Drug-Induced Interstitial Lung Disease During Combined Androgen Blockade With Bicalutamide and Leuprorelin Acetate for Prostate Cancer

Maeda, Koki; Osafune, Takashi; Masuda, Yuki; Takeda, T.; Kageyama, Susumu; Narita, Mitsuhiro; Kawauchi, Akihiro

doi:10.5980/jpnjurol.110.36

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some studies, leuprorelin was associated with interstitial lung diseases, granulomas, or other kinds of cutaneous eruptions (erythematous macules, infiltrated plaques, subcutaneous nodules, and sterile abscesses) [10][11][12][13][14], but no case reports of LV associated with leuprorelin are reported, so our manuscript should be considered innovative as first article on this topic. Possible association between leuprorelin treatment and LV could be related to alterations on immune system as proposed for interstitial lung disease by Shioi et al [10].…”

Section: Discussionmentioning

confidence: 99%

Diffuse Leukoplakia of the Bladder Ostium-Sparing in Patient Treated with Leuprorelin for Breast Cancer

Nacchia

Giacomo

Cerbo

et al. 2021

Case Reports in Urology

View full text Add to dashboard Cite

Case. A 55-year-old woman came to our attention in April 2020 referring haematuria, frequency and urgency. The patient referred previous treatment with leuprorelin 3.75 mg/2 ml for breast cancer three years ago. Urine culture was performed and resulted always negative for pathogens. Cystoscopy revealed a whitish plaque lesion on the fundus, dome, trigone, and left lateral wall of the bladder. Histology of the biopsy confirmed the diagnosis of leukoplakia of the bladder. The plan is to follow her up repeating a cystoscopy every three months and biopsy in 6 months. Literature search revealed very little information on pathogenesis and prognosis of this condition due to its rare occurrence. The main objective of our case study was to describe individual situation of a woman affected by diffuse leukoplakia of the bladder ostium-sparing with a previous treatment with leuprorelin 3.75 mg/2 ml for breast cancer and to show safety of follow-up by cystoscopy and biopsy. Conclusions. We showed a case of a woman treated with leuprorelin and with diffuse leukoplakia of the bladder. We support the recommended long-term follow-up and surveillance based on the literature review by cystoscopy with or without biopsy.

show abstract